智通财经网·2025-12-18 03:41Group 1 - The autoimmune disease market is a blue ocean, with new targets and mechanisms driving rapid industry development. The global autoimmune market reached $132.3 billion in 2022 and is expected to grow to $176.7 billion by 2030, with a CAGR of 3.68% [2][3] - The drug development paradigm is shifting from broad-spectrum anti-inflammatory treatments to precision regulation, with significant room for improvement in efficacy and safety of existing drugs [2][3] Group 2 - Psoriasis affects approximately 125 million patients globally, with a focus on large molecule antibody drugs and a surge in small molecule oral TYK2 inhibitors that may replace existing treatments [3] - Atopic dermatitis impacts over 204 million people worldwide, with Dupilumab achieving sales exceeding $12.9 billion in the first three quarters of 2025, and new oral drugs like STAT6PROTAC showing superior efficacy [3] - The clinical demand for autoimmune diseases remains largely unmet, with domestic companies actively innovating in drug development, focusing on target innovation and expanding indications [4] Group 3 - Companies to watch include: 1. Xiansheng Pharmaceutical: Focused on differentiated targets with potential candidates like SIM0278, SIM0709, and SIM0711 [4] 2. Kangnuo Pharmaceutical: Rapidly increasing sales of Dupilumab, with peak sales expected to reach 5 billion yuan; CM512 shows promise as a leading TSLPxIL-13 dual antibody [4] 3. Quansheng Biotechnology: QX013N targets c-kit for CSU treatment, with additional dual antibody projects expected to submit IND applications between 2025 and 2026 [4] 4. Yifang Biotechnology: D-2570 (TYK2 inhibitor) is in Phase II clinical trials for UC, with promising Phase II data for psoriasis [4] 5. Sanofi Genzyme: Rapidly advancing IL-5 monoclonal antibody for asthma, with NDA submission expected by 2027 [4]